Anti-Eribulin payload antibody in PK study in ADC drug development

Anti-eribulin antibodies are used in pharmacokinetic (PK) studies to measure the levels of eribulin and its conjugates in biological samples accurately. Eribulin mesylate, derived from the marine sponge Halichondria okadai, is a synthetic analog of the marine natural product halichondrin B, used primarily as a chemotherapeutic agent for treating metastatic breast cancer and liposarcoma. Like camptothecin, eribulin can also be used as a payload in antibody-drug conjugates (ADCs), where it is linked to an antibody that specifically targets cancer cells.

**Product list of GeneMedi's anti-Eribulin antibody**
Cat No.	Product Description	Fc	Products Information
GTU-Bios-Eribulin-Ab	Anti-Eribulin-monoclonal-antibody (mAb)	hFc/mFc	Details

All Payloads of ADCs

Application

Competitive immunoassay validation (CompetitiveELISA) and other Immunoassay,
PK & PD assay for MMAE payload of Antibody-drug Conjugate (ADC)

Highlight:

Purity: ≥95% (SDS-PAGE)
High affinityand specificity validated
High sensitivity verified by ADCs binding assay

Application
Technical Resource

Why Use Anti-Eribulin Antibody in ADC drug development?

1. Specificity: Anti-eribulin antibodies are designed to specifically bind to eribulin and its derivatives. This specificity is crucial for accurately determining the pharmacokinetics of the drug, particularly when it is part of an ADC. Accurate measurement ensures that the distribution and metabolism of both the free drug and the ADC can be studied distinctly.
2. Sensitivity: These antibodies are capable of detecting low concentrations of eribulin, which is important for assessing its therapeutic and toxic levels in the body, especially given the drug's potent cytotoxicity.
3. Efficacy and Safety Evaluation: Studying the pharmacokinetics of eribulin, especially when linked to an ADC, helps in evaluating how effectively the drug targets the tumor cells and the rate at which the payload is released into the tumor environment. This evaluation is critical in assessing both the efficacy and safety of the treatment.

How to use Anti-Eribulin Antibody in ADC drug development?

Development of Immunoassays: Anti-eribulin antibodies are used to develop various types of immunoassays, such as ELISA, which can quantitatively measure eribulin concentrations in plasma, serum, and other tissue samples. These assays help in understanding the bioavailability and elimination patterns of the drug.
Sample Collection and Analysis: In a PK study, biological samples are collected at predetermined intervals after drug administration. These samples are then analyzed using immunoassays that incorporate anti-eribulin antibodies. This analysis helps in determining the concentration of eribulin at different times, providing data on its absorption, distribution, metabolism, and excretion.
Data Utilization: The PK data obtained helps in characterizing the kinetic profile of eribulin and optimizing dosage schedules. It is also essential for understanding the drug's interaction with biological systems, predicting potential side effects, and ensuring the maximum therapeutic benefit.

Using anti-eribulin antibodies in PK studies of ADCs or as standalone treatments is vital for the successful development of eribulin-based therapies. It ensures that the therapeutic development is guided by precise and reliable pharmacokinetic data, leading to safer and more effective cancer treatments.